References
- Miura S, Karnik SS, Saku K. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst 2011;12:1–7
- Shimamoto K, Ando K, Fujita T, et al. Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014;37:253–392
- Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009;32:826–34
- Mohanan A, Gupta R, Dubey A, et al. TRC120038, a novel dual AT(1)/ET(A) receptor blocker for control of hypertension, diabetic nephropathy, and cardiomyopathy in ob-ZSF1 rats. Int J Hypertens 2011:751513
- Breschi MC, Calderone V, Digiacomo M, et al. New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties. J Med Chem 2006;49:2628–39
- Monge M, Lorthioir A, Bobrie G, Azizi M. New drug therapies interfering with the renin–angiotensin–aldosterone system for resistant hypertension. J Renin Angiotensin Aldosterone Syst 2013;14:285–9
- Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension 2014;63:698–705
- Jhund PS, Claggett B, Packer M, et al. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail 2014;16:671–7
- Campbell WB, Currie MG, Needleman P. Inhibition of aldosterone biosynthesis by atriopeptins in rat adrenal cells. Circ Res 1985;57:113–18
- Olson LJ, Ho BY, Cashdollar LW, Drewett JG. Functionally active catalytic domain is essential for guanylyl cyclase-linked receptor mediated inhibition of human aldosterone synthesis. Mol Pharmacol 1998;54:761–9
- Chatterjee S, Moeller C, Shah N, et al. Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med 2012;125:817–25
- Fujino M, Miura S, Kiya Y, et al. A small difference in the molecular structure of angiotensin II receptor blockers induces AT1 receptor-dependent and -independent beneficial effects. Hypertens Res 2010;33:1044–52
- Miura S, Nakao N, Hanzawa H, et al. Reassessment of the unique mode of binding between angiotensin II type 1 receptor and their blockers. PLoS One 2013;8:e79914
- Miura S, Okabe A, Matsuo Y, et al. Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res 2013;36:134–9
- Ojima M, Igata H, Tanaka M, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011;336:801–8
- Miura S, Fujino M, Hanzawa H, et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 2006;281:19288–95
- Tokudome T, Kishimoto I, Horio T, et al. Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation 2008;117:2329–39
- Pool JL, Guthrie RM, Littlejohn TW III, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998;11:462–70
- Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007;3:486–92